Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating BCMA-targeted CAR T cells with or without lenalidomide for multiple myeloma; currently active but not recr…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies [Phase 1]
A Phase 1 study evaluating feasibility and safety of collecting autologous hematopoietic stem cells and combining them with CAR T-cell thera…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy [Phase 2]
Phase 2 study evaluating talquetamab in people with multiple myeloma who have previously received BCMA CAR T-cell therapy is currently recru…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Discontinuation Study [NA]
University College Cork is conducting a Discontinuation Study for conditions including multiple myeloma; the trial is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma [Phase 2]
A Phase 2 clinical trial investigating multi-immune, multi-target immunotherapy for high-risk multiple myeloma is planned but not yet recrui…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Feasibility of a Multi-omics Platform for Hematological Malignancies [NA]
This clinical trial update assesses the feasibility of a multi-omics platform for hematological malignancies and is currently recruiting. It…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease [NA]
This entry describes the FAST-M trial evaluating prolonged overnight fasting with a Mediterranean diet for patients with multiple myeloma or…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment [NA]
A clinical trial evaluating a PREHABilitation protocol using Adapted Physical Activity for multiple myeloma patients eligible for intensive …
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Karyopharm Expanded Access Program for Selinexor
This update covers Karyopharm's Expanded Access Program for selinexor (Xpovio), including eligibility and current availability for listed ca…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
This clinical trial update reports on outcomes of maintenance therapy following autologous stem cell transplantation in patients with multip…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients [Phase 1, Phase 2]
A Phase 1/2 trial in China is evaluating BCMA-CART with or without autologous stem cell transplant in young patients with multiple myeloma, …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma [Phase 2]
This is a Phase 2 clinical trial update for SELIBORDARA, evaluating a triplet of selinexor, bortezomib, and daratumumab in refractory multip…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms [EARLY_Phase 1]
A Phase 1 clinical trial evaluating CAR BCMA-70 CAR-T cells for high-risk plasma cell neoplasms is listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma [Phase 1]
Phase 1 trial evaluating tumor-associated antigen-specific cytotoxic T-lymphocytes for multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial [Phase 1, Phase 2]
An update on the SCOPE trial evaluating selinexor, pomalidomide, and dexamethasone with or without carfilzomib in relapsed/refractory multip…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating GC012F in relapsed/refractory multiple myeloma is currently recruiting, sponsored by Gracell Biotechno…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update describes an early-phase study of IBI3003 for relapsed or refractory multiple myeloma that is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) [Phase 2]
This is a Phase 2 clinical trial update (REVIVE) evaluating teclistamab in combination with daratumumab for high-risk smoldering/wholedown m…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: TriPRIL CAR T Cells in Multiple Myeloma [Phase 1]
This document summarizes an ongoing Phase 1 clinical trial evaluating TriPRIL CAR T Cells in patients with multiple myeloma, including relap…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) [Phase 2, Phase 3]
A Phase 2/3 clinical trial update announcing a study comparing Linvo-VR against the DVRd regimen in transplant-eligible adults with newly di…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial (NCT05530421) evaluating selinexor, venetoclax, and dexamethasone (XVenD) in t(11;14)-positive relapsed/refractory …
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating maintenance therapy with isatuximab and lenalidomide after autologous stem cell transplant in MRD-positive…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial is evaluating subcutaneous isatuximab with weekly carfilzomib and dexamethasone in adults with relapsed and/or refr…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring [NA]
Carevive Systems is conducting a real-world study evaluating remote symptom monitoring for patients with breast cancer, lung cancer, gastroi…